Dicalcium Citrate

Brand names: Fosteum Plus · Active ingredient: Dicalcium Malate Dihydroxide, Zinc Glycinate Citrate

In short: Fosteum PLUS is indicated for the clinical dietary management of the metabolic processes of osteopenia and osteoporosis. Fosteum PLUS may be taken with additional calcium and/or vitamin D3 if directed by a physician after determining dietary intake of both nutrients.

LabelPrimus Pharmaceuticals, Inc.
Label updatedMar 21, 2025

What is Dicalcium Citrate used for?

Fosteum PLUS is indicated for the clinical dietary management of the metabolic processes of osteopenia and osteoporosis.

Fosteum PLUS may be taken with additional calcium and/or vitamin D3 if directed by a physician after determining dietary intake of both nutrients. In clinical trials of the genistein (54 mg/day) used in Fosteum PLUS, patients received 1,000 mg of calcium carbonate and 800 IU vitamin D3 per day in two divided doses. See Dosage and Administration for additional information.

Fosteum PLUS can be taken with or without other foods. Fosteum PLUS may be taken with any beverage desired.

Dicalcium Citrate dosage

Fosteum PLUS should be taken twice a day, approximately 12 hours apart, and may be taken with or without food. Fosteum PLUS has no food limitations. There are no postural limitations.

Warnings & precautions

Do not take this medicine if: Causes of osteopenia or osteoporosis other than menopause or aging should be considered.

Fosteum PLUS is contraindicated for anyone having a hypersensitivity to any ingredient in the product.

Fosteum PLUS has not been specifically studied in patients with a history of cancer of the breast or reproductive organs. Major studies on isoflavone intake have been published including one epidemiological study involving 18,312 postmenopausal women who were followed for an average of 9.2 years. Based on these findings, Fosteum PLUS may be suitable for the management of osteopenia and osteoporosis in these populations. The decision to use Fosteum PLUS in these clinical situations should be made in consultation with the patient’s physician.

Fosteum PLUS is not intended to treat vitamin D3 deficiency, generally characterized in the literature by serum levels of 25-hydroxycholecalciferol below 9 ng/mL.

In patients suffering from diseases associated with unregulated overproduction of calcitriol, supplemental vitamin D3 may worsen hypercalcemia and/or hypercalciuria. Therefore, Fosteum PLUS is not recommended in these patients.

Animal studies suggest that genistein may produce developmental abnormalities of the male and female genital tracts if consumed during early stages of pregnancy. Effects in infants of nursing mothers are uncertain. Therefore, Fosteum PLUS is not recommended in pregnant and lactating women. Women capable of becoming pregnant should use appropriate contraception when taking Fosteum PLUS. The genistein in Fosteum PLUS has not been tested in women capable of becoming pregnant.

Vitamin K1(phylloquinone) is a specific antagonist of warfarin on the Gla proteins of the clotting system. Vitamin K2 (menaquinone) has similar, but weaker, effects on these proteins. …

Dicalcium Citrate side effects

CALCIUM COMPOUNDS

Neither dicalcium malate nor pentacalcium hydroxide triphosphate are known to cause specific adverse events. All calcium can be constipating, especially if used in excess. Proper hydration is recommended with any calcium-containing product.

GENISTEIN AGLYCONE

In a three-year clinical trial, 389 subjects were randomized to either genistein plus calcium and vitamin D3 n=198, or calcium and vitamin D3 alone n=191. A total of 52 subjects in both groups discontinued due to adverse events. Study discontinuation in these subjects was due to gastrointestinal symptoms, including abdominal and epigastric pain, dyspepsia, vomiting and constipation. Discontinuation was reported in both groups. The incidence of adverse events was statistically higher in the genistein group throughout the study. The major adverse events are shown in the table below without attribution of causality.

Adverse

Events | Year 1 | Year 2 | Year 3

Genistein+Ca/D3

(n=178) | Ca/D3

(n=172) | Genistein+Ca/D3

(n=150) | Ca/D3

(n=154) | Genistein+Ca/D3

(n=71) | Ca/D3

(n=67)

Abdominal Pain | 4 (2.2%) | 2 (1.1%) | 2 (1.3%) | 1 (0.6%) | 1(1.4%) | 1(1.5%)

Dyspepsia | 2 (1.1%) | 1 (0.6%) | 7 (4.7%) | 2 (1.3%) | 2(2.8%) | 1(1.5%)

Constipation | 5 (2.8%) | 3 (1.7%) | 8 (5.3%) | 3 (1.9%) | 2(2.8%) | 1(1.5%)

Some of these adverse event occurrences may be attributable to the intake of 1,000 mg per day of calcium carbonate by subjects in both groups. …

Drug interactions

Thiazide diuretics inhibit renal calcium excretion. Care should be taken to monitor serum calcium in patients with high dietary calcium intake, and those who are taking both supplemental calcium and thiazides. Calcium can interfere with absorption of thyroid hormone. People taking thyroid medications should allow at least one hour between doses of thyroid medications and Fosteum Plus.

The genistein in Fosteum PLUS was tested in in vitro pooled human liver microsome assays for CYP1A2, 2A6, 2C8, 2C9, 2D6, and 3A4. Inhibition of the 1A2, 2A6, 2D6 and 3A4 isozymes was low, however, inhibition of CYP450 2C8 and 2C9 was observed with IC50s of 2.5 and 2.8 μM, respectively. Results from a steady-state pharmacokinetic study in post-menopausal women showed that the level of circulating genistein was in the low nanomolar range and undetectable at most time points in many subjects. These data suggest that circulating genistein does not reach the concentration required to produce any clinically significant interactions with co-administered drugs. The effects of the principal circulating metabolites of genistein on CYP450-mediated metabolism are currently unknown.

Warfarin specifically antagonizes the carboxylation of Gla proteins thus rendering them inactive. …

About this medicine

Fosteum PLUS consists of a specially formulated proprietary blend of dicalcium malate and pentacalcium hydroxide triphosphate, sodium phosphate, high purity genistein aglycone from a natural, non-soy source, citrated zinc bisglycinate, trans-menaquinone-7 (vitamin K2), and cholecalciferol (vitamin D3). Genistein aglycone reduces osteoclast activity and stimulates osteoblast activity. Citrated zinc bisglycinate works synergistically with genistein aglycone, while both citrated zinc bisglycinate and vitamin D3 also work independently to promote mineralization activity in bone. Vitamin K2 works with vitamin D3 in aiding bone-building enzymes in the deposition of calcium in bone during remodeling. Vitamin D3 also facilitates calcium absorption from the intestine.

DICALCIUM MALATE

Each Fosteum PLUS capsule contains 200 mg of dicalcium malate for a total daily intake of 400 mg. Dicalcium malate is chemically described as calcium 2,4-dihydroxy-4-oxobutanoate. The formula for dicalcium malate is Ca2C4H6O7; its molecular weight is 246.2. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ddfb19cc-e77a-4d69-ad42-f4448faf0b47. Read the full official label on DailyMed.